Home

The possibility of generation of secondary ionizing radiation on tantalum oxide nanoparticles in radiation therapy of malignant tumors

Written by Lukyanenko K.S., Apanasevich V.I., Lagureva A.V., Plotnikova O.S., Pankratov I.V., Rudyuk V.P., Stebunov L.S., Chernobaev A.A., Lykanov P.A., Davydova V.N., Medkov M.A., Kustov V.N., Temchenko V.V.

  UDK: 616-006-085.849.114:549.221 | Pages: 38–40 | Full text PDF | Open PDF 

Annotation:

Objective. The administration of radiation sensitizer into a tumor succeeded by ray treatment leads to the additional secondary radiation inside the neoplasm that improves the effect of the ray treatment.
Methods. Measuring the dose of ionizing radiation was conducted by using the phantom (WP 600). The 2.5 % suspension of nanoparticles (NPs) of tantalum oxide (Ta2O5) or control solution (0.9 % NaCl solution) were placed into a spherical sample. Dimensions of NPs were determined with the tool Zetasizer NanoZS and constituted 71±1 nm (А) и 81±1 nm (В). Со60 was used as a source of radiation. The measuring was carried out with the ionization chamber FC65-P, which recorded the total intensity of γ-radiation. The measuring was carried out at the open gate, the passage of γ-camera under the test specimen at a distance of 0.5 cm. Data were processed in Wolfram Mathematica 9.0.
Results. The total radiation for samples containing NPs Ta2O5 was higher than those obtained in the measurement of ionizing radiation by a 0.9 % solution of NaCl. The increase for particles with a size of 65 nm was 5.5 % for particles with a size of 71 nm – 5.2 %, for a particle with a size of 81 nm – 7 %. The reason for increase in the emission intensity when passing hard γ-radiation through the low Ta2O5 is the generation of the secondary low-energy ionizing radiation.
Conclusions. NPs Ta2O5 is a promising medicine for the treatment of local radio modification malignancies.

Links to authors:

K.S. Lukyanenko1, V.I. Apanasevich2, 5, A.V. Lagureva2, O.S. Plotnikova2, I.V. Pankratov3, V.P. Rudyuk3, L.S. Stebunov3, A.A. Chernobaev3, P.A. Lykanov4, V.N. Davydova4, M.A. Medkov6, V.N. Kustov7, V.V. Temchenko7

1 Far Eastern Federal University (8 Sukhanova St. Vladivostok 690950 Russian Federation),
2 Pacific State Medical University (2 Ostryakova Ave. Vladivostok 690950 Russian Federation),
3 Primorsky Regional Oncology Center (59 Russkaya St. Vladivostok 690015 Russian Federation),
4 G.B. Elyakov Pacific Institute of Bioorganic Chemistry FEB RAS (159 Vladivostok 100th anniversary Ave. Vladivostok 690022 Russian Federation),
5 Regional Clinical Center of Specialized Medical Care (30/37 Uborevicha St. Vladivostok 690091 Russian Federation),
6 Institute of Chemistry FEB RAS (159 Vladivostok 100th anniversary Ave. Vladivostok 690022 Russian Federation),
7 Vladivostok Branch of Russian Customs Academy (16в Strelkovaya St. Vladivostok 690034 Russian Federation)


1. Apanasevich V., Avramenko V., Lukyanov P. [et al.]. Enhance the absorption of gamma-ray energy inside the tumor using gold nanoparticles and iodine particles // Cancer and Oncology Research. 2014. Vol. 2, No. 2. P. 17–20.
2. Bonnet C., Tóth E. Smart contrast agents for magnetic resonance imaging // CHIMIA International Journal for Chemistry. 2016. Vol. 70, No. 1, P. 102–108.
3. Chelkowski S., Bandrauk A.D., Corkum P.B. Photon momentum sharing between an electron and an ion in photoionization: from one-photon (photoelectric effect) to multiphoton absorption // Phys. Rev. Lett. 2014. Vol. 113, No. 26. P. 263005.
4. Gambini D.J. Basic concepts of radiology physics // J. Radiol. 2010. Vol. 91, No. 11 ( Pt 2). P. 1186–1188.
5. Jain S., Hirst D. G., O'Sullivan J.M. Gold nanoparticles as novel agents for cancer therapy // Br. J. Radiol. 2012. Vol. 85, No. 1010. P. 101–113.
6. Mitchell J., Knight R.T., Kimlin K. Effects of iodinated contrast media on radiation therapy dosimetry for pathologies within the thorax // The Radiographer. 2006. Vol.53, No. 2. P. 30–34.

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.